Enhanced Expression of CXCL10 in Inflammatory Bowel Disease

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

(2011) Michael Yellin et al.   ARTHRITIS AND RHEUMATISM

CXCR3 ligands: redundant, collaborative and antagonistic functions

(2011) Joanna R Groom et al.   IMMUNOLOGY AND CELL BIOLOGY

Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease

(2010) Sebastian Schroepf et al.   INFLAMMATORY BOWEL DISEASES

An antibody to IP-10 is a potent antagonist of cell migrationin vitroandin vivoand does not affect disease in several animal models of inflammation

(2009) Fergus R. Byrne et al.   AUTOIMMUNITY

Transcript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitis

(2009) Alexandra Zahn et al.   BMC GASTROENTEROLOGY

Beyond TNF, Th1 and Th2 in inflammatory bowel disease

(2008) M. Shale et al.   GUT

TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events

(2008) Karen A. Cavassani et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte-epithelial cell interaction

(2008) Pinelopi Manousou et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY